公开(公告)号：US20130239690A1

公开(公告)日：2013-09-19

申请号：US13818964

申请日：2011-08-25

申请人： Shigeru Tadano ,  Itsuro Kajiwara ,  Kazuhiro Fujisaki ,  Seishin Takao ,  Gen Nakamura ,  Yu Jiang ,  Mikio Suga

发明人： Shigeru Tadano ,  Itsuro Kajiwara ,  Kazuhiro Fujisaki ,  Seishin Takao ,  Gen Nakamura ,  Yu Jiang ,  Mikio Suga

IPC分类号： G01N29/04

CPC分类号： G01N29/04 ,  A61B5/0051 ,  A61B5/055 ,  G01R33/56358

摘要： An MRE excitation apparatus (100) comprises an excitation device (110) that generates vibration, and a transmitter (120) that is made using a non-magnetic material and that, with one end-section being fastened to the excitation device (110) and the other end-section being connected with a living body (300), and that extends in direction that vibration is transmitted from the excitation device (110) and transmits longitudinal vibration from the excitation device (110) to the living body (300). The frequency of the vibration is 125 Hz or greater, the amplitude of the vibration is 0.2 mm or greater, and the primary natural frequency of the longitudinal vibration of the transmitter (120) is further on the higher side than the frequency band of the vibration from the excitation device (110).

摘要翻译： MRE励磁装置（100）包括产生振动的励磁装置（110）和使用非磁性材料制成的发射器（120），并且一个端部紧固到激励装置（110）上， 并且另一端部与活体（300）连接，并且在从激励装置（110）传递振动的方向延伸，并且将来自激励装置（110）的纵向振动传递到生物体（300） 。 振动的频率为125Hz以上，振动的振幅为0.2mm以上，发送器（120）的纵向振动的主要固有频率进一步在比振动的频带高的一侧 来自激励装置（110）。

公开(公告)号：US09307423B2

公开(公告)日：2016-04-05

申请号：US14131370

申请日：2012-07-09

申请人： Satoshi Nagata ,  Jing Wang ,  Yu Jiang ,  Xiaoming She ,  Lan Chen ,  Hirohito Suda

发明人： Satoshi Nagata ,  Jing Wang ,  Yu Jiang ,  Xiaoming She ,  Lan Chen ,  Hirohito Suda

IPC分类号： H04W24/02 ,  H04W16/14 ,  H04W72/08 ,  H04W72/04

CPC分类号： H04W24/02 ,  H04W16/14 ,  H04W72/0426 ,  H04W72/082 ,  Y02D70/122 ,  Y02D70/1262

摘要： Provided are a method for coordinating inter-cell interference in a heterogeneous network (HetNet) and the heterogeneous network. The method includes: forming M normal base stations and low-power nodes within coverage of the respective normal base stations in the heterogeneous network into a coordinated group; combining mute/non-mute states of bandwidths of the M normal base stations to obtain a plurality of states of the coordinated group; a user of each of the normal base stations feeding at least one first CQI back to the normal base station; a user of each of the low-power nodes feeding one or more second CQIs back to the low-power node; using the first CQI and the second CQIs as a basis to make capacity estimation of the coordinated group; and setting the mute/non-mute states of the bandwidths of the M normal base stations in accordance with a state of the coordinated group corresponding to an optimal system capacity so as to perform data transmission. In the method for coordinating interference provided by the present invention, M transmission points each including one or more normal base stations and low-power nodes covered by the respective normal base stations can be formed into a coordinated group, thereby extending processing for the normal base stations up to all the transmission points in the coordinated group.

摘要翻译： 提供了一种用于协调异构网络（HetNet）和异构网络中的小区间干扰的方法。 该方法包括：将异构网络中相应正常基站的覆盖范围内的M个正常基站和低功率节点形成协调组; 组合M个正常基站的静音/非静音带宽，以获得协调组的多个状态; 每个正常基站的用户将至少一个第一CQI馈送回正常基站; 每个低功率节点的用户将一个或多个第二CQI馈送回所述低功率节点; 使用第一CQI和第二CQI作为进行协调组的容量估计的基础; 以及根据与最佳系统容量相对应的协调组的状态来设置M个正常基站的带宽的静音/非静音状态，以执行数据传输。 在本发明提供的干扰协调方法中，可以将由各个正常基站覆盖的一个或多个正常基站和低功率节点组成的M个发送点形成为协调组，从而扩展正常基站的处理 到达协调组中的所有传输点的站。

公开(公告)号：US08528082B2

公开(公告)日：2013-09-03

申请号：US12672506

申请日：2008-07-23

申请人： Yu Jiang

发明人： Yu Jiang

IPC分类号： G06F11/00 ,  G06F12/14 ,  G06F7/04

CPC分类号： G06F21/606

摘要： A security disposing method and device for the input data involves generating an interference data according to a predefined rule when inputting the data, and mixing the input data with the interference data and sending the mixed data, and parsing out the interference data according to the predefined rule after receiving the mixed data, and separating the input data according to the parsed interference data.

摘要翻译： 用于输入数据的安全处置方法和装置包括在输入数据时根据预定规则生成干扰数据，并将输入数据与干扰数据进行混合并发送混合数据，并根据预定义解析出干扰数据 接收混合数据后的规则，并根据解析的干扰数据分离输入数据。

公开(公告)号：US07329656B2

公开(公告)日：2008-02-12

申请号：US11231601

申请日：2005-09-21

申请人： Mohammad R. Marzabadi ,  Yu Jiang ,  Chien-An Chen ,  Kai Lu ,  Kim Andersen

发明人： Mohammad R. Marzabadi ,  Yu Jiang ,  Chien-An Chen ,  Kai Lu ,  Kim Andersen

IPC分类号： A61K31/4545 ,  A61K31/444 ,  A61K31/5377 ,  C07D211/04 ,  C07D401/04 ,  C07D413/14

CPC分类号： C07D401/04 ,  C07D211/26 ,  C07D211/62 ,  C07D401/12 ,  C07D401/14

摘要： This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.

摘要翻译： 本发明涉及作为MCH1受体的配体的芳硫基苄基哌啶衍生物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。 本发明还提供了治疗患有肥胖症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。

公开(公告)号：US07105544B2

公开(公告)日：2006-09-12

申请号：US10345063

申请日：2003-01-14

申请人： Mohammad R. Marzabadi ,  John M. Wetzel ,  Chien-An Chen ,  Yu Jiang ,  Kai Lu

发明人： Mohammad R. Marzabadi ,  John M. Wetzel ,  Chien-An Chen ,  Yu Jiang ,  Kai Lu

IPC分类号： A61K31/445 ,  C07D211/26

CPC分类号： C07D211/26 ,  C07D211/28 ,  C07D211/90 ,  C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D401/04 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/06 ,  C07D405/12 ,  C07D409/06 ,  C07D409/10 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/06 ,  C07D417/10 ,  C07D471/04 ,  C07D495/04

摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

公开(公告)号：US20060173027A1

公开(公告)日：2006-08-03

申请号：US10518939

申请日：2003-07-03

申请人： Mohammad Marzabadi ,  Yu Jiang ,  Kai Lu ,  Chien-An Chen ,  John De Leon ,  John Wetzel ,  Kim Andersen

发明人： Mohammad Marzabadi ,  Yu Jiang ,  Kai Lu ,  Chien-An Chen ,  John De Leon ,  John Wetzel ,  Kim Andersen

IPC分类号： A61K31/4747

CPC分类号： C07D221/20 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D491/10

摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.

摘要翻译： 本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。 本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用有效治疗受试者抑郁症和/或焦虑的量的本发明化合物。 本发明还提供了治疗患有尿失禁的受试者的方法。

公开(公告)号：US20050154022A1

公开(公告)日：2005-07-14

申请号：US11034611

申请日：2005-01-13

申请人： Mohammad Marzabadi ,  John Wetzel ,  Chien-An Chen ,  John DeLeon ,  Yu Jiang ,  Kai Lu

发明人： Mohammad Marzabadi ,  John Wetzel ,  Chien-An Chen ,  John DeLeon ,  Yu Jiang ,  Kai Lu

IPC分类号： C07D211/26 ,  C07D401/12 ,  A61K31/4545 ,  C07D41/14

CPC分类号： C07D401/12 ,  C07D211/26

摘要： This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

摘要翻译： 本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的4-芳基哌啶和相关的杂环化合物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。 本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的有效治疗受试者的抑郁症和/或焦虑症的本发明化合物。

公开(公告)号：US20140133419A1

公开(公告)日：2014-05-15

申请号：US14117686

申请日：2012-05-10

申请人： Satoshi Nagata ,  Yu Jiang ,  Jing Wang ,  Xiaoming She ,  Lan Chen

发明人： Satoshi Nagata ,  Yu Jiang ,  Jing Wang ,  Xiaoming She ,  Lan Chen

IPC分类号： H04L5/00

CPC分类号： H04L5/0073 ,  H04W52/244 ,  H04W72/1257

摘要： Provided are a method for coordinating inter-cell interference in a radio network, a transmission point and the radio network. The method includes: a step A of a normal base station performing scheduling based on feedback information of users of the normal base station and obtain a user scheduling result of the normal base station including a parameter about actual transmission characteristics of the normal base station; a step B of the normal base station obtaining a performance estimating parameter including a parameter about actual transmission characteristics of each of the one or plurality of low-power base stations for both cases of normal base station without transmission and normal base station with transmission; a step C of the normal base station using the performance estimating parameter and the user scheduling result of the normal base station as a basis to determine weighting throughputs of all transmission points for the case of normal base station without transmission and weighting throughputs of all the transmission points for the case of normal base station with transmission; and a step D of the normal base station comparing the weighting throughputs of all the transmission points, obtaining a transmission determination result and performing data transmission based on the transmission determination result.

摘要翻译： 提供了一种用于协调无线电网络，传输点和无线电网络中的小区间干扰的方法。 该方法包括：正常基站的步骤A，基于正常基站的用户的反馈信息进行调度，获取正常基站的用户调度结果，该结果包括关于正常基站的实际传输特性的参数; 正常基站的步骤B获得包括一个或多个低功率基站中的每个低功率基站的实际传输特性的参数的性能估计参数，用于无传输的普通基站和正常基站的传输; 使用性能估计参数和正常基站的用户调度结果的正常基站的步骤C作为基础来确定在没有传输的情况下的所有发送点的所有发送点的加权吞吐量，以及所有传输的加权吞吐量 正常基站传输点数; 以及正常基站的步骤D，比较所有传输点的加权吞吐量，获得传输确定结果并根据传输确定结果执行数据传输。

公开(公告)号：US20120149354A1

公开(公告)日：2012-06-14

申请号：US13391747

申请日：2010-12-25

申请人： Yilun Ying ,  Liang Huo ,  Yu Jiang ,  Xing Liu ,  Yu Yao ,  Zhihong Zhang ,  Dawei Zhu ,  Yehui Zhang ,  Yang Luan ,  Song Yang

发明人： Yilun Ying ,  Liang Huo ,  Yu Jiang ,  Xing Liu ,  Yu Yao ,  Zhihong Zhang ,  Dawei Zhu ,  Yehui Zhang ,  Yang Luan ,  Song Yang

IPC分类号： H04W4/04 ,  H04W4/18 ,  G06F15/177

CPC分类号： G08G1/096716 ,  G08G1/096758 ,  G08G1/096775

摘要： A vehicle information system includes: a vehicle-mounted device, a network processing device and a service center which is adapted for providing service for the vehicle-mounted device. A service configuration channel is configured between the network processing device and the service center and is adapted for transmitting configuration data which are adapted for configuring service that is provided for the vehicle-mounted device. The service configuration channel is established on basis of connection to internet. A service channel system is configured between the vehicle-mounted device and the service center. A complete solution for providing information service may be provided by the vehicle information system, thereby improving the quality of user experience while using a vehicle.

摘要翻译： 车辆信息系统包括：适用于为车载装置提供服务的车载装置，网络处理装置和服务中心。 服务配置信道被配置在网络处理设备和服务中心之间，并适于发送适于配置为车载设备提供的服务的配置数据。 服务配置通道是基于与互联网的连接建立的。 在车载设备和服务中心之间配置服务通道系统。 可以由车辆信息系统提供用于提供信息服务的完整解决方案，从而在使用车辆时提高用户体验的质量。

公开(公告)号：US07446204B2

公开(公告)日：2008-11-04

申请号：US11230849

申请日：2005-09-20

申请人： Mohammad R. Marzabadi ,  Chien-An Chen ,  Yu Jiang ,  Kai Lu ,  Kim Andersen

发明人： Mohammad R. Marzabadi ,  Chien-An Chen ,  Yu Jiang ,  Kai Lu ,  Kim Andersen

IPC分类号： C07D211/14 ,  A61K31/451

CPC分类号： C07D211/26 ,  C07D211/34 ,  C07D401/12 ,  C07D403/12

摘要： This invention is directed to Amino substituted Aryloxybenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.

摘要翻译： 本发明涉及作为MCH1受体的配体的氨基取代的芳氧基苄基哌啶衍生物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。 本发明还提供了治疗患有肥胖症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。